-
In Vitro Cancer Drug Response: Growth vs Death
2026-09-29
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a time-aware framework that separates proliferative arrest from cell killing, improving interpretation of drug-response experiments and the design of follow-up assays.
-
HyperScript RT SuperMix for qPCR in Exosomes
2026-09-29
HyperScript RT SuperMix for qPCR can strengthen the mRNA arm of exosomal miRNA studies by supporting consistent cDNA synthesis from difficult RNA inputs. This article explains how to match reverse-transcription chemistry to RNA class, sample quality, and mechanistic assay design in sepsis-related lung injury research.
-
Safe DNA Gel Stain: Practical Gel Workflow
2026-09-28
Safe DNA Gel Stain (SKU A8743) provides a practical option for DNA and RNA gel visualization in agarose or acrylamide while supporting blue-light imaging as an alternative to routine UV exposure. It is suitable for research workflows, but users should account for solvent compatibility, storage limits, and reduced effectiveness with 100–200 bp DNA bands.
-
CFDA SE Cell Tracer Kit: Practical Workflow
2026-09-28
The CFDA SE Cell Tracer Kit provides covalent fluorescent labeling for researchers tracking cell proliferation or lineage over several days. Use it for durable labeling in compatible in vitro or in vivo workflows, not when staining must be reversible or rapidly cleared; optimize conditions for each cell type because the dossier does not specify a working concentration or incubation time.
-
Malate and the Metabolic-Immune Interface
2026-09-27
A translational perspective on how malate can help researchers interrogate mitochondrial redox balance and TCA-cycle flux—and how to connect those measurements carefully to emerging evidence on PDHA1 succinylation and immune escape in cholangiocarcinoma.
-
U0126-EtOH for MEK/ERK Research Workflows
2026-09-26
U0126-EtOH offers a direct way to test whether MEK1/2-dependent ERK activity contributes to a phenotype, from neuronal stress assays to limb-patterning studies. This guide connects inhibitor handling and readouts to recent spatial-transcriptomics findings while distinguishing established product use from experiments that still need validation.
-
BAY-826 for Tie-2 Signaling and Retinal Survival
2026-09-25
Explore how BAY-826, a potent small molecule inhibitor, can support carefully controlled studies of angiopoietin-linked retinal signaling. This article focuses on causal assay design—separating Müller-cell effects, neuronal responses, and pathway evidence—rather than treating inhibitor potency as proof of mechanism.
-
Quizartinib (AC220) Workflows for FLT3-Driven AML
2026-09-25
Use Quizartinib (AC220) to test FLT3 dependence with linked target-engagement, signaling, and cell-response measurements—not viability alone. This practical guide covers dose selection, assay controls, resistance-aware interpretation, and common troubleshooting pitfalls.
-
Letrozole Workflows for Aromatase Research
2026-09-24
Use Letrozole to test estrogen synthesis as an upstream driver of hormone-responsive phenotypes, rather than treating estrogen-receptor signaling as the only control point. This practical guide links assay design, solvent handling, and biomarker selection to the distinction between aromatase inhibitors and SERMs.
-
N2703 and the Adipose-Neural Axis in Arrhythmia
2026-09-24
A translational perspective on the adipose-neural signaling implicated in arrhythmia—and on how to evaluate 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) as an exploratory research tool without assuming an unvalidated mechanism.
-
DiscoveryProbe FDA-approved Drug Library for Screening
2026-09-23
Translate a mechanistic muscle-biology question into a practical drug-repositioning screen with 2,320 clinically established compounds. A sulfasalazine study illustrates how reporter hits can be advanced through differentiation assays, atrophy models, and cautious clinical-data analysis.
-
CFDA SE Cell Tracer Kit: Protocol Guide
2026-09-23
The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell lineage tracing, cell proliferation studies, and selected in vitro or in vivo tracking workflows. It is intended for durable covalent marking rather than short-term, reversible labeling, and assay-specific dye concentration, exposure time, and toxicity must be optimized experimentally.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-22
Zhao and colleagues describe a standardized whole-blood stimulation protocol for measuring how metabolic interventions reshape cytokine responses to defined immune stimuli. By preserving the multicellular blood environment while controlling stimulation, inhibition, sample handling, and cytokine quantification, the method provides a practical framework for cohort studies and mechanistic immunometabolism research.
-
DiscoveryProbe FDA-approved Drug Library Workflow
2026-09-22
Build a mechanism-aware screening workflow around a clinically annotated compound collection rather than relying on phenotype alone. The DiscoveryProbe library pairs ready-to-use 10 mM DMSO stocks with live-cell mTORC1 sensing, orthogonal validation, and practical troubleshooting for drug repositioning screening and cancer research.
-
Adipose-Neural Axis in Cardiac Arrhythmias
2026-09-21
Fan et al. establish a stem cell-based coculture model showing how epicardial adipose tissue can communicate with sympathetic neurons and cardiomyocytes through a leptin–NPY pathway. The study identifies Y1R, NCX, and CaMKII as mechanistically connected intervention points while linking increased EAT thickness and circulating leptin/NPY levels with atrial fibrillation.